The fight against cancer seems to be never-ending to some degree. This particular disease has been a thorn in the medical industry’s side for years and years. Its damaging effects have caused people to lose their limbs, lose their livelihood and lose their lives. Fortunately, today is a new day and some of the best cancer-fighting medications are being used on a consistent basis. These medications fall under the umbrella of antibody-based therapies. Also referenced to as targeted-cancer therapies, these medications deliver much more impressive results than their predecessors. When it comes to producing some of the best therapies, Seattle Genetics sits atop the apex in prominence.
Seattle Genetics is a Washington-based company that falls under the oncology term. It researches, it develops, and it commercializes antibody-drug conjugates. CEO Clay Siegall is the leader here, and he is also the company’s president and founder. Siegall has been in the industry for a long time that spans back three decades. “Having enough ambition to work intensely is how you succeed,” says Siegall. Seattle Genetics displays this notion to the highest degree. In present time, the company has a robust pipeline that’s full of advanced medications. This pipeline has up to 20 new drugs as well as a plethora of strategic partnerships. These partnerships will be used to distribute the goods to those who need it. This is the new wave of targeted-cancer therapies. “Chemotherapies and other systemic treatments are headed for the dust bin,” says Siegall.
Restoring good health to those who truly need it is the goal. Siegall’s late-father suffered from this disease for years. Past treatments like Chemotherapy are extremely taxing on a human’s system. Anemia, radical surgery and amputation are simply not acceptable in today’s medical community and this is why targeted-cancer therapies were invented.
Eric Lefkofsky is a man on a mission to make the world a better place. One of his top priorities is to help people deal with life after a cancer diagnosis. His latest foray into the business world includes a data-driven way to deal with treatments.
Eric’s wife was diagnosed breast cancer, which created an atmosphere of fear for him and his family. They immediately wanted access to the data and all pertinent information, but found that nearly impossible. He went to work on solving that problem knowing that it could help people around the world.
Technology and data join together to form a perfect team. This union is called Tempus and is the result of Eric Lefkofsky’s desire to make life easier for cancer patients. It is designed to help with treatment plans and create understanding.
Tempus is only one part of a long list of business successes that are part of Mr. Lefkosfsky’s portfolio. His companies include Tempus, Lightbank, Groupon, Uptake Technologies, Mediaocean, Echo Global Logistics, and InnerWorkings. His talents have taken him to the top of his field.
Educational opportunities started Eric down the path to success. He attended University of Michigan where he graduated with honors. Eric Lefkofsky later went on to receive a Juris Doctor from University of Michigan Law School.
Charity is Part of Success
Eric lives by the motto that success should be shared. He and his wife Liz established the Lefkofsky Foundation. It is a charitable trust that focuses on enhancing the lives of children around the globe by funding an array of causes. Community based organizations such as Children’s Memorial Hospital in Chicago, The Museum of Science and Industry, The Art Institute of Chicago, and Steppenwolf Theatre Company have benefited from Eric’s generosity.
Sharing With Others
One of the ways Eric has chosen to share with others is through his writings and teaching. He has taught classes at several universities and recently had a book published. His diverse knowledge has changed lives and he continues to be a driving force in today’s business world.
Seattle Genetics has been at the forefront leading research and fight against cancer. This company was founded by Clay Siegall in 1998. Siegall studied Genetics at George Washington University and zoology in the University of Maryland. His knowledge in cancer treatment has been acquired from the extensive experience gained in various institutions. The work performed by Siegall has had a positive effect globally due to his discovery and cancer therapy inventions.
Dr. Siegall is a pioneer in cancer research and therapeutic drug development programs. As a chief Executive officer in Seattle Genetics Company, he is actively involved to ensure that cancer patients get the best treatment. His passion in this field makes it possible to come up with helpful solutions to curb the illness. The advancements in cancer research and therapies conducted by Seattle Genetics are as a result of his tireless efforts
He has held several senior roles and participate in numerous programs and he was a has been a board member of reputable institutions like Ultragenyx. Previously, he had worked with several other pharmaceuticals and accomplished more successes in leadership positions. The interest and focus in cancer make him carry out more research to aid in reducing suffering encountered by cancer patients.
Due to his efforts, he has earned a number of awards from numerous institutions. He has a serious drive towards cancer treatment and he is actively involved in searching for better cancer therapy. In addition, Clay Siegall is involved in books publications and has written 67 books and holds more than nine patents. He also works on the Editorial Board of three scientific journals and is a member of the Board of Scientific Counselors for the Cancer Treatment Research Foundation.
The main concern that made him engage in major research activities and drug development is the desire to achieve change and alleviate suffering for cancer patients. Seattle Genetics Company in collaboration with another entity has invented antibody-drug conjugates (ADCs), ADCETRIS® which was approved in 2011. A lot of mobilization has been done during his leadership to obtain funds for supporting Seattle Genetics. The funds helped in cancer research, treatment, and drug development using the modern technology.